TRCT
ACTU

Tower Research Capital (TRC)’s Actuate Therapeutics ACTU Stock Holding History

Tower Research Capital (TRC)’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.8K Buy
5,754
+4,118
+252% +$17.1K ﹤0.01% 3652
2025
Q4 		$10K Sell
1,636
-7
-0.4% -$48 ﹤0.01% 3848
2025
Q3 		$11K Buy
1,643
+1,630
+12,538% +$11.8K ﹤0.01% 3928
2025
Q2 		$79 Sell
13
-2,542
-99% -$22.2K ﹤0.01% 5165
2025
Q1 		$17.3K Buy
+2,555
New +$20.5K ﹤0.01% 3111
2024
Q4 		– Sell
-297
Closed -$2.21K – 6084
2024
Q3 		$2.21K Buy
+297
New +$2.35K ﹤0.01% 5029

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tower Research Capital (TRC)'s ACTU Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Actuate Therapeutics (ACTU) stake by 252% in Q1 2026, buying an estimated $17.1K and bringing the position to 5,754 shares worth $15.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3652.

Tower Research Capital (TRC) first reported a position in ACTU in Q3 2024 and has held it in 6 quarters since. The position peaked at $17.3K in Q1 2025. 61 funds tracked by Wall St. Rank hold ACTU as of Q1 2026.

  • Tower Research Capital (TRC) held 5,754 shares of Actuate Therapeutics worth $15.8K as of Q1 2026.
  • Tower Research Capital (TRC) bought 4,118 Actuate Therapeutics shares in Q1 2026, an estimated $17.1K.
  • Actuate Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3652 holding.
  • Tower Research Capital (TRC) first reported a position in Actuate Therapeutics in Q3 2024 and has held it in 6 quarters since.
  • Tower Research Capital (TRC)'s Actuate Therapeutics position peaked at $17.3K in Q1 2025.
  • 61 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.